Windhover’s Pharmaceutical Strategic Alliances (PSA)

Top 10 reasons to attend Pharmaceutical Strategic Alliances

• The Best Networking in the Business: The editorial team behind IN VIVO, STARTUP and "The Pink Sheet" bring you an unprecedented level of expertise and top analysis to our conference content.
• Fast-Track Executive Training: There is no better way to quickly train your R&D/BD teams in two days than to hear healthy debates with key opinion leaders on how to move forward in the right direction.
• Expand your Business and Your Career: Meet the key decisionmakers at numerous networking opportunities including the Welcome Reception and Gala Reception.
• Excellent Case Studies: PSA is strategically packed with lessons learned, future biopharma trends, and actionable data to help improve your R&D/BD/Biotech business models.
• Get Closer to your Patients: Hear novel externalization/ cooperation examples among traditionally wary constituents: venture capital partners, payors, data providers, academic centers, and governments.
• Mitigate Risk: Understand the specifics driving biopharma deal-making to better calibrate ongoing negotiations.
• Drive Value for your Drug: It’s a new commercial landscape so don’t fall behind the curve. Find out what the potential is for your products in a new marketplace of payer priorities. How will health care reform affect your launch?
• Access Innovation to Fuel Sustainable Growth: Hear about the unprecedented scale of restructurings, adaptive business models, and how companies are tapping into new relationships and sources/cultures of innovation for driving their pipelines.
• Unique Structure: PSA’s participants and agenda address the most timely and relevant issues for today’s industry. High-level strategy and details are well balanced in our panels.
• Benchmark your R&D/BD Business Models against the Best, the Brightest and your Competitors: What are the key components for the new models? Get a clear picture of what it takes to win by benchmarking your strategies to the best in class. How are non-traditional partnerships supplanting the typical biotech-pharma alliance of years past?

To be updated